Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
REDWOOD CITY, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three
Toggle Summary Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity
Paper Published in Peer-Reviewed Journal , Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS) DCCR is the first K-ATP Channel activator being developed for PWS  Company expects to report top-line data from Phase III trial evaluating DCCR for PWS patients in Q2 2020
Toggle Summary Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference
REDWOOD CITY, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
REDWOOD CITY, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the
Toggle Summary Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
REDWOOD CITY, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third
Toggle Summary Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock
REDWOOD CITY, Calif. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of its previously announced underwritten
Toggle Summary Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
REDWOOD CITY, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of
Toggle Summary Soleno Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common
Toggle Summary Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has, for the second time,